role of sglt2i in hfpef and its impact on renal outcomes
Published Streamed 2 years ago • 1.3K plays • Length 1:03:43Download video MP4
Download video MP3
Similar videos
-
1:02:19
cardiovascular, renal and metabolic benefits of sglt2i for type 2 diabetes and heart failure
-
1:26:29
apsc cme webinar : is the evidence for sglt2 inhibitors enough for a paradigm shift? 26th june 2020
-
1:30:24
apsc cme series: sglt2i
-
1:06:11
iscp 2021 dapagliflozin et al. the growing therapeutic spectrum of sglt2i
-
1:18:05
apsc journal club - landmark trials of sglt2 inhibitors in hfref
-
39:00
iscp 2021 - shall we now add sglt2 inhibitors to our water?
-
4:06
clap in 60s - sglt2 inhibitors as leaders in hfref? (part 1)
-
1:39:39
cardiovascular and renal risk factor management in diabetes: concepts and treatment strategies
-
23:00
professor niko marx - the therapeutic importance of sglt2 inhibition – heart failure the new target!
-
1:31:41
hfpef – what have we delivered ?
-
51:52
the serendipitous story of sglt2i in the treatment of heart failure
-
2:49
clap in 60s - sglt2 inhibitors as leaders in hfref? (part 2)
-
14:53
fundamentals of sglt2i's and glp-1ra's for cv risk
-
8:15
sglt2 inhibitors and heart failure
-
50:30
protocols for safe use of sglt2i and glp1ra in the hospital setting
-
1:16:25
hfref and the obstacles of initiation to optimization of gdmt
-
5:59
implications of using sglt2 inhibitors with hfpef and hfref
-
1:04:16
pharmacological therapies in management of hfref
-
1:13:35
iscp 2021 - poised to take over the world in heart failure management?